Group items tagged

This Funding Opportunity Announcement (FOA) seeks applications for the design and development of technologies to monitor health or deliver care in a real-time, accessible, effective, and minimally obtrusive way for older adults with a chronic heart, lung, blood, or sleep (HLBS) condition. These technologies may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems and should have the goal of fostering healthy and independent living for aging adults with HLBS conditions. The development of such technologies should incorporate specific human factors for aging adults including disabilities, mild impairments, as well as chronic HLBS conditions. Technology usability for these populations must be incorporated early in the development of the design. Usability considerations include but are not limited to patient-facing displays, hearing and visual impairments, tactile limitations, literacy, and design preferences between men and women. These improvements in technology design could yield more accurate and earlier detection of changes that may interfere with healthy and independent living for older adults.

This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders. Successful applicants will provide biospecimens for whole genome sequencing or other omics assays. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public database such as dbGaP.

This Funding Opportunity Announcement (FOA) is to support studies that are essential, yet also sufficient, for investigators to make definitive decisions about the designs of important clinical trials within NHLBI's mission, the prevention and treatment of heart, lung, blood, and sleep disorders. This mechanism may be used to test the feasibility of novel and efficient (pragmatic) trial designs, as well as determine the feasibility of an intervention, intervention parameters, subject availability, or other information essential to complete the design of a trial. Applications should demonstrate that the proposed pilot studies are both necessary and sufficient to permit definitive decisions about the design of the subsequent clinical trial. Applicants who propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial will not be considered appropriate for this announcement. The NHLBI anticipates that the R34 award period will yield robust investigator-initiated clinical trial grant applications for the evaluation of interventions for the treatment or prevention of heart, lung, blood, or sleep disorders.

This Funding Opportunity Announcement (FOA) invites basic research project grant (R01) applications to investigate the fundamental mechanisms underlying the pathogenesis of HIV-related heart, lung, and/or blood (HLB) diseases alone and in the context of antiretroviral therapy (ART). Investigations may be conducted on various primary cell types, biospecimens, computational models, and animal models, particularly those used for HIV research. The goal is to provide the critical basic science foundation and guide the design of new therapeutic approaches for HIV-related HLB conditions in adults and children.

This Funding Opportunity Announcement (FOA) invites basic research project grant (R21) applications to investigate the fundamental mechanisms underlying the pathogenesis of HIV-related heart, lung, and/or blood (HLB) diseases alone and in the context of antiretroviral therapy (ART). Investigations may be conducted on various primary cell types, biospecimens, computational models, and animal models, particularly those used for HIV research. The goal is to provide the critical basic science foundation and guide the design of new therapeutic approaches for HIV-related HLB conditions in adults and children.

The purpose of this Funding Opportunity Announcement (FOA) is to support research to identify and evaluate the basic underlying molecular and physiological mechanisms by which the virome may influence heart, lung, and blood (HLB) health and resilience.

The objective of the Social Behavioral Research Grant is to provide seed monies to junior investigators working on various disciplines of social science examining risk factors affecting lung health including: Psychosocial research Behavioral research Health services and health policy research Epidemiology / Biostatics research Public Health Education research

The purpose of this FOA is to invite applications that will seek to prospectively define and/or validate pulmonary or immune system attributes associated with pre-symptomatic disease states or resilience, with the goal of informing the development of primary prevention strategies for chronic lung diseases.

The purpose of this FOA is to invite applications that will seek to prospectively define and/or validate pulmonary or immune system attributes associated with pre-symptomatic disease states or resilience, with the goal of informing the development of primary prevention strategies for chronic lung diseases.

This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders. 

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to build in-country capacity through the creation of a trans-disciplinary investigative team to guide the conduct of late-stage translation phase 4 research (T4TR) in low income countries (as defined by The World Bank) through skills development programming, needs assessment, and capacity building. Studies will be required to address chronic non-communicable heart, lung, blood and sleep diseases and disorders in low income countries.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to build in-country capacity through the creation of a trans-disciplinary investigative team to guide the conduct of late-stage translation phase 4 research (T4TR) in low income countries (as defined by The World Bank) through skills development programming, needs assessment, and capacity building. Studies will be required to address chronic non-communicable heart, lung, blood and sleep diseases and disorders in low income countries.

This Funding Opportunity Announcement (FOA) invites applications to establish research teams of the Small-Cell Lung Cancer (SCLC) Consortium to conduct research whose overall goals are: 1) to improve SCLC therapeutics, focusing on understanding how the molecular vulnerabilities of this cancer could be used to develop targeted agent combinations; and/or, 2) to gain a better understanding of the rapid development of clinical resistance to drug and radiation therapy.

The purpose of this Funding Opportunity Announcement (FOA) is to support research to identify and evaluate the basic underlying molecular and physiological mechanisms by which the virome may influence heart, lung, and blood (HLB) health and resilience.    

This Funding Opportunity Announcement (FOA) seeks late-stage T4 Translation research (T4TR) and implementation studies that will lead to generalizable new knowledge to accelerate the adoption/adaptation, and sustained, high-fidelity use of proven-effective interventions for the prevention, treatment, and control of heart, lung, blood, and sleep disorders or diseases (HLBS conditions). It calls for multi-level strategies for delivery of proven-effective interventions to promote the prevention and management of HLBS conditions. The system-level change(s) being evaluated are to be designed, and findings reported so that others would have a contextually-informed understanding of workflow, workforce, and trade-off considerations. These considerations should reflect cultural and organizational contextual factors and values as they inform feasibility and flexibility of adopting, adaptable and sustainable, proven-effective interventions to address HLBS conditions.

This Funding Opportunity Announcement (FOA) seeks applications that propose to develop and test T4 implementation strategies to identify facilitators and overcome barriers in the adaptation, integration, scale-up, and sustainability of proven-effective interventions and guidelines for preventing and/or managing heart, lung, and blood diseases and/or sleep disorders (HLBS conditions). The proposed implementation strategies must be adaptable and responsive to community needs and contexts, and must account for cultural and organizational factors. For purposes of this FOA, T4 Implementation Research is defined as research to identify strategies to enhance sustainable uptake of proven-effective interventions into routine clinical practice.

This Funding Opportunity Announcement (FOA) invites applications for research projects to join the Small-Cell Lung Cancer (SCLC) Consortium. Goals of the SCLC Consortium pertinent to this FOA are: 1) to learn the mechanistic and biological underpinnings of SCLC formation, progression and heterogeneity; 2) to investigate how molecular vulnerabilities could be used to develop targeted agents or combinations; and 3) to understand clinical resistance to drug and radiation therapy and its rapid development.

The goal of the K12 Institutional Career Development Program in HIV-related Heart, Lung, Blood, and Sleep (HLBS) research is to encourage institutions to develop and sustain programs that support inter-disciplinary, intensive mentored research training and career development for junior PhDs and MDs in AIDS co-morbidities as well as cell and gene therapies for HIV cure and prevention of HIV transfusion transmission.

The purpose of this Funding Opportunity Announcement (FOA) is to foster research on human long non-coding RNAs (lncRNAs) to understand their roles in controlling the gene regulatory networks underpinning normal Heart, Lung, Blood and Sleep (HLBS) homeostatic and disease processes. 

The purpose of this Funding Opportunity Announcement (FOA) is to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers. The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this FOA) must be focused on cancers of the breast, prostate and other genitourinary organs, and lung. In addition, cancers with rapidly rising incidenc

The National Institute of Allergy and Infectious Diseases (NIAID) solicits applications from single institutions and consortia of institutions to participate in the Nonhuman Primate Transplantation Tolerance Cooperative Study Group (NHPCSG) program. The NHPCSG is a multi-center, cooperative program for research on nonhuman primate (NHP) models of kidney, pancreatic islet, heart, and lung transplantation. The goals of the NHPCSG are to evaluate the preclinical safety and efficacy of existing and newly developed immune tolerance induction regimens and to elucidate the underlying mechanisms of the induction, maintenance, and/or loss of tolerance in these models. The long-range goal of this program is to develop and evaluate immune tolerance induction regimens that will result in enhanced long-term graft survival in clinical transplantation.